

REAL WORLD TESTING PLAN – October 29, 2022

ONC - Health IT Certification Program

Table of Contents

| Gener | al Information | 1 |
|----------|---|---|
| Justific | cation for Real World Testing Approach | 2 |
| Standa | ards Updates (SVAP) | 2 |
| Measu | ures Used in Overall Approach | 3 |
| 1. | Description of the Measurement/Metric | 3 |
| 2. | Associated Certification Criteria | 4 |
| 3. | Justification for Selected Measurement/Metric | 4 |
| 4. | Care Setting(s) | 4 |
| 5. | Expected Outcomes | 5 |
| Schedi | ule of Key Milestones | 5 |

General Information

| Developer Name: | D.A.W. SYSTEMS, INC. | |
|---|---|--|
| Product Name: | SCRIPTSURE CLOUD ERX | |
| Version Name: | V.2.1 | |
| Certified Health IT Product List (CHPL) ID: | 15.04.04.2919.Scri.02.01.0.220413 | |
| Developer Real World Testing Page URL: | https://www.dawsystems.com/pdf/realworldtestingplan102022.pdf | |
| Certified Health IT Criteria: | 170.315: (a)(1), a(4), a(5), b(3), d(1-8), d(12-13), g(2-5) | |
| Associated Real World Testing Measure(s) | 170.315(b)(3) | |
| for RWT (Scope of Real-World Testing): | | |
| RWT Plan report ID Number: | DAWRWT102022 | |



Justification for Real World Testing Approach

D.A.W. SYSTEMS, INC. (hereinafter "DAW") provides ScriptSure Cloud ERX (hereinafter "ScriptSure") ONC Certified Health IT Solution (modular) to medical professionals in ambulatory care settings. The ScriptSure application is an Electronic Prescribing solution. The ScriptSure application is either sold directly to end users to be used as a stand-alone application or it is licensed to and integrated/interfaced with an EHR partner application. The audience and user base of the ScriptSure application covers a range of specialties. These specialties include family practice, internal medicine, pain management, hospice, palliative care, dentistry, behavioral health and more. All end users of ScriptSure electronically prescribe using the application. End user facilities using ScriptSure range from solo-practitioners to large group and multi-provider facilities.

The applicable and required criteria that will be tested is 170.315(b)(3).

DAW will focus Real World Testing on the electronic prescribing of both controlled and non-controlled medications in ambulatory settings across multiple specialties and multiple facility sizes. DAW will measure usability, successful transmission of Electronic Prescriptions across the Surescripts ERX network, receiving messages back from pharmacies and analyze and track error rates of electronic prescribed medications. Qualitative data will be collected through analysis of prescription transactions and quantitative data from end user feedback (where applicable) and analysis of support cases. This approach is justified based on the criteria, scope of the application and DAW userbase audience (ambulatory settings in which all of use ScriptSure to electronically prescribe). Completion will demonstrate compliance and maintenance to the associated (170.315(b)(3)).

Standards Updates (SVAP)

| Standard (and version): | Not Applicable |
|--|----------------|
| Updated certification criteria & associated product: | Not Applicable |
| Health IT Module CHPL ID: | Not Applicable |
| Method used for standard update: | Not Applicable |
| Date of ONC ACB notification: | Not Applicable |
| Date of customer notifications: | Not Applicable |
| Conformance measure: | Not Applicable |
| USCDI updated certification criteria: | Not Applicable |



Measures Used in Overall Approach

1. Description of the Measurement/Metric

The following detail the testing Measurements that will be used to determine compliance and to produce the Real World Testing Final Report. Each of the measurements below will apply to data derived from users subject to the Real World Testing defined in the Care Settings section below.

| Measure | Measurement Description of Measurement/Metric | |
|---------|---|---|
| 1. | Successful Prescriptions sent by End Users | This is calculated by the total number of prescriptions that were successful divided by the total number of prescriptions that were sent electronically to pharmacies by the users subject to the Real World Testing. Results will be represented in fractions and converted to percentages based of the Care Settings examined. Descriptions of acceptable rates based on industry practices will be evaluated and determined, and the results will be measured against the industry rates and overall compliance with the requirement of associated criteria. Prescriptions may be broken down into controlled vs noncontrolled and structured SIG vs free form SIG counts. |
| 2. | Error Prescriptions | This is determined by mining the end users prescription routing and examining error responses from the electronic network and pharmacy receivers. The errors will be calculated and separated into categories for analysis to determine if the error was caused by a ScriptSure issue, network issue, or pharmacy issue and within those categories if the issue is the result of a programmatic issue or a user/pharmacist training issue. The results will begin by calculating the total number of errors for the Care Settings and divide that by the total number of prescriptions the Care Settings executed. From there, the error messages will be separated into categories to determine the causes of errors and analyze. |
| 3. | CancelRx | This is determined by tracking the number of prescriptions transmitted for the Care Settings with a message type of CancelRx. |
| 4. | RxChange | Measure number of RxChange requests received and how many responded to and how many not responded to for the Care Settings. |
| 5. | Structured SIG vs. Free Form | Total number of prescriptions and codified SIG and how many were free form specific notation with regard to QUOM. Calculated by measuring total number of prescriptions and percentage that are Structured vs Free Form. |
| 6. | RxFill | Calculated by total number of prescriptions at the Care Setting and the deriving how many of those RxFill notifications were received for. |



2. Associated Certification Criteria

The associated certification criteria are controlled and non-controlled medications sent using per 170.315(b)(3).

3. Justification for Selected Measurement/Metric

All Providers (Care Settings) utilize the application to electronically prescribe medications in line with 170.315(b)(3). Analysis of Measurements below will demonstrate Real World use and offers the ability to test the efficacy and utilization of the application and its compliance with ONC criteria 170.315(b)(3). Each of the following are Measurements are within the required tests for (b)(3) and therefore justified in the Real World Testing.

| Measurement | | Justification | |
|-------------------------------------|--------------------|---|--|
| 1. Successful | | Measuring the rate of successful prescriptions will demonstrate that | |
| | Prescriptions sent | users are able to send prescriptions successfully to pharmacies. | |
| | by End Users | | |
| 2. Error Prescriptions Measuring th | | Measuring the rate of prescriptions that result in an error will | |
| | | demonstrate that users are able to successfully send prescriptions to | |
| | | pharmacies without receiving errors. | |
| 3. | CancelRx | Tracking will demonstrate that users are able to successfully | |
| | | send/request cancellations of new prescriptions. | |
| 4. | RxChange | Measuring will demonstrate that users are able to respond to | |
| | | pharmacies' RxChange requests successfully. | |
| 5. | Structured SIG vs. | Tracking will demonstrate that providers use Structured SIG more often | |
| | Free Form | than Free Form to send prescriptions with a valid QUOM. | |
| 6. | RxFill | Measure the number of fill status notifications received and compare to | |
| | | the total # of prescriptions sent. Demonstrates compliance and | |
| | | adoption by pharmacies and ScriptSure compliance with receiving RxFill | |
| | | responses from across the ERX network. | |

4. Care Setting(s)

The care setting selected for Real World Testing represent differing user types (DDS, MD, DO) and specialties (Dentist, Psychiatrist, Hospice). Recent new users (within 3 months of utilizing ScriptSure) and long-term users (in excess of 1 year) will be included in the testing results. The care settings that will be subject to Real World Testing are listed below and will represent a viable cross section of the Real World users of the ScriptSure ONC Certified application. A minimum of 5 active providers at a minimum of 3 practices will be tested. (DAW may decide to include more providers and facilities in the testing.) Our testing will measure ambulatory sites that we support and target and market to. This will cover a sufficient and viable sample of active users of the certified EHR:

- A. Solo-practice dentist (ambulatory setting).
- B. Solo-Practice Psychiatrist (ambulatory setting).
- C. Hospice facility (ambulatory setting).



5. Expected Outcomes

| Measurement | | Expected Outcome | |
|--|---|---|--|
| 1. | Successful | > 99% of all prescriptions sent by a provider will be successful. We expect | |
| | Prescriptions sent | that there will be equal success of prescriptions across both controlled | |
| | by End Users | and non-controlled prescriptions and across all Care Settings and user | |
| | | types. | |
| 2. Error < 1% of all prescriptions sent will result in an error. | | < 1% of all prescriptions sent will result in an error. | |
| | Prescriptions | | |
| 3. | CancelRx | < 1% of new prescriptions will be cancelled. | |
| 4. | RxChange | 25% RxChange response rate. | |
| 5. | . Medication 85% of Medication History transactions will be successful. | | |
| | History Responses | | |
| 6. | Structured SIG vs. | 70% of prescriptions will use Structured SIG and 30% will use free form. | |
| | Free Form | | |
| 7. | RxFill | 25% of prescriptions will show RxFill messages . | |

Schedule of Key Milestones

| Key Milestone | Care Setting | Date/Timeframe |
|--|---------------------------|----------------|
| Define specific end users that will be tracked | All Care Settings defined | Q1 2023 |
| throughout the course of the Real World Testing | | |
| Begin collection of data as laid out by the plan for | All Care Settings defined | Q2 2023 |
| analysis | | |
| Capture data at end of quarter for analysis and | All Care Settings defined | Q3 2023 |
| comparison to previous quarter | | |
| Create final reports and submit by 2/1/2024 | All Care Settings defined | Q4 2023 |

Attestation

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

ada far

Authorized Representative Name: Adam Forman, COO

Authorized Representative Email: aforman@dawsystems.com

Authorized Representative Phone: 866-755-1500

Authorized Representative Signature:

Date: October 29, 2022